Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases

Critical Reviews in Clinical Laboratory Sciences

Volumn 53, Issue 6, 2016, Pages 396-408

  Kjaergaard, A D ^a   Johansen, J S ^b,c   Bojesen, S E ^b,c,d   Nordestgaard, B G ^b,c,d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

Acute phase protein; biomarker; causality; chronic inflammation; Mendelian randomization

Indexed keywords

BIOLOGICAL MARKER; CHI3L1 PROYEIN; INTERLEUKIN 13 RECEPTOR ALPHA2; LIPID; PLASMA PROTEIN; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG; YKL 40 PROTEIN; CHI3L1 PROTEIN, HUMAN; CHITINASE 3 LIKE PROTEIN 1;

AGE; ALCOHOL LIVER DISEASE; AMINO TERMINAL SEQUENCE; BLOOD VESSEL WALL; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LIVER DISEASE; MACROPHAGE; MENDELIAN RANDOMIZATION ANALYSIS; MOLECULAR BIOLOGY; MOLECULAR WEIGHT; NONHUMAN; OBSERVATIONAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REFERENCE VALUE; REVIEW; STELLATE CELL; VENOUS THROMBOEMBOLISM; ADULT; AGED; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CARDIOVASCULAR DISEASES; CHITINASE-3-LIKE PROTEIN 1; HUMANS; LIVER DISEASES; MIDDLE AGED; YOUNG ADULT;

EID: 84986627804     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.1080/10408363.2016.1190683     Document Type: Review

References (105)

1. G.K.Hansson Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009;7:328–31
2. Y.A.Lee, M.C.Wallace, S.L.Friedman Pathobiology of liver fibrosis:a translational success story. Gut 2015;64:830–41
3. R.Ross Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115–26
4. S.Z.Goldhaber Risk factors for venous thromboembolism. J Am Coll Cardiol 2010;56:1–7
5. G.Piazza, S.Z.Goldhaber Venous thromboembolism and atherothrombosis:an integrated approach. Circulation 2010;121:2146–50
6. S.Z.Goldhaber, H.Bounameaux Pulmonary embolism and deep vein thrombosis. Lancet 2012;379:1835–46
7. H.T.Sørensen, E.Horvath-Puho, L.Pedersen,. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events:a 20-year cohort study. Lancet 2007;370:1773–9
8. C.Lind, L.E.Flinterman, K.F.Enga,. Impact of incident venous thromboembolism on risk of arterial thrombotic diseases. Circulation 2014;129:855–63
9. H.T.Sørensen, E.Horvath-Puho, K.K.Søgaard,. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism:a population-based case-control study. J Thromb Haemost 2009;7:521–8
10. H.Tao, J.J.Yang, K.H.Shi,. The significance of YKL-40 protein in liver fibrosis. Inflamm Res 2014;63:249–54
11. F.Heymann, F.Tacke Immunology in the liver - from homeostasis to disease. Nat Rev Gastroenterol Hepatol 2016;13:88–110
12. W.Seo, W.I.Jeong Hepatic non-parenchymal cells:master regulators of alcoholic liver disease? World J Gastroenterol 2016;22:1348–56
13. M.Rehli, S.W.Krause, R.Andreesen Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997;43:221–5
14. G.H.Renkema, R.G.Boot, F.L.Au,. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998;251:504–9
15. R.G.Boot, T.A.van Achterberg, B.E.van Aken,. Strong induction of members of the chitinase family of proteins in atherosclerosis:chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 1999;19:687–94
16. A.J.Millis, M.Hoyle, L.Kent In vitro expression of a 38,000 dalton heparin-binding glycoprotein by morphologically differentiated smooth muscle cells. J Cell Physiol 1986;127:366–72
17. L.M.Shackelton, D.M.Mann, A.J.Millis Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 1995;270:13076–83
18. K.M.Malinda, L.Ponce, H.K.Kleinman,. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999;250:168–73
19. K.C.Nishikawa, A.J.T.Millis gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003;287:79–87
20. C.G.Lee, C.A.Da Silva, C.S.Dela Cruz,. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 2011;73:479–501
21. R.Shao YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol 2013;4:122
22. J.S.Johansen Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006;53:172–209
23. J.S.Johansen, S.Møller, P.A.Price,. Plasma YKL-40:a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 1997;32:582–90
24. J.S.Johansen, P.Christoffersen, S.Møller,. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000;32:911–20
25. C.Nøjgaard, J.S.Johansen, E.Christensen,. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003;39:179–86
26. C.Nøjgaard, N.B.Høst, I.J.Christensen,. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 2008;19:257–63
27. Y.Wang, R.S.Ripa, J.S.Johansen,. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J 2008;42:295–302
28. A.Hedegaard, R.S.Ripa, J.S.Johansen,. Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand J Clin Lab Invest 2010;70:80–6
29. H.Y.Park, C.D.Jun, S.J.Jeon,. Serum YKL-40 levels correlate with infarct volume, stroke severity, and functional outcome in acute ischemic stroke patients. PLoS One 2012;7:e51722
30. A.D.Kjaergaard, J.S.Johansen, S.E.Bojesen, B.G.Nordestgaard Elevated plasma YKL-40, lipids and lipoproteins, and ischemic vascular disease in the general population. Stroke 2015;46:329–35
31. A.D.Kjaergaard, J.S.Johansen, S.E.Bojesen, B.G.Nordestgaard Observationally and genetically high YKL-40 and risk of venous thromboembolism in the general population:cohort and Mendelian randomization studies. Arterioscler Thromb Vasc Biol 2016;36:1030–6
32. A.D.Kjaergaard, S.E.Bojesen, B.G.Nordestgaard, J.S.Johansen YKL-40 and alcoholic liver and pancreas damage and disease in 86,258 individuals from the general population:cohort and Mendelian randomization studies. Clin Chem 2014;60:1429–40
33. A.Tran, S.Benzaken, M.C.Saint-Paul,. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 2000;12:989–93
34. J.S.Johansen, M.K.Williamson, J.S.Rice, P.A.Price Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992;7:501–12
35. B.E.Hakala, C.White, A.D.Recklies Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993;268:25803–10
36. B.W.Morrison, P.Leder neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 1994;9:3417–26
37. S.Harvey, M.Weisman, J.O'Dell,. Chondrex:new marker of joint disease. Clin Chem 1998;44:509–16
38. A.K.Mohanty, G.Singh, M.Paramasivam,. Crystal structure of a novel regulatory 40-kDa mammary gland protein (MGP-40) secreted during involution. J Biol Chem 2003;278:14451–60
39. F.De Ceuninck, S.Gaufillier, A.Bonnaud,. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 2001;285:926–31
40. A.D.Recklies, C.White, H.Ling The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 2002;365:119–26
41. M.Faibish, R.Francescone, B.Bentley,. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression:a potential therapeutic agent in cancers. Mol Cancer Ther 2011;10:742–51
42. M.N.Kim, K.E.Lee, J.Y.Hong,. Involvement of the MAPK and PI3K pathways in chitinase 3-like 1-regulated hyperoxia-induced airway epithelial cell death. Biochem Biophys Res Commun 2012;421:790–6
43. F.Fusetti, T.Pijning, K.H.Kalk,. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem 2003;278:37753–60
44. N.C.Chang, S.I.Hung, K.Y.Hwa,. A macrophage protein, Ym1, transiently expressed during inflammation is a novel mammalian lectin. J Biol Chem 2001;276:17497–506
45. R.Shao, K.Hamel, L.Petersen,. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009;28:4456–68
46. R.A.Francescone, S.Scully, M.Faibish,. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 2011;286:15332–43
47. D.N.Clarke, A.Al Ahmad, B.Lee,. Perlecan domain V induces VEGf secretion in brain endothelial cells through integrin α5β1 and ERK-dependent signaling pathways. PLoS One 2012;7:e45257
48. B.Lee, D.Clarke, A.Al Ahmad,. Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in rodents. J Clin Invest 2011;121:3005–23
49. C.H.He, C.G.Lee, C.S.Dela Cruz,. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep 2013;4:830–41
50. I.Kushner The phenomenon of the acute phase response. Ann N Y Acad Sci 1982;389:39–48
51. C.Gabay, I.Kushner Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–54
52. M.B.Pepys, G.M.Hirschfield C-reactive protein:a critical update. J Clin Invest 2003;111:1805–12
53. C.Nordenbaek, J.S.Johansen, P.Junker,. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J Infect Dis 1999;180:1722–6
54. B.Kornblit, D.Hellemann, L.Munthe-Fog,. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts. Immunobiology 2013;218:1227–34
55. H.Ling, A.D.Recklies The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J 2004;380:651–9
56. J.S.Johansen, P.E.Høyer, L.A.Larsen,. YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 2007;55:1213–28
57. K.Kawamura, T.Shibata, O.Saget,. A new family of growth factors produced by the fat body and active on Drosophila imaginal disc cells. Development 1999;126:211–19
58. F.Badariotti, M.Kypriotou, C.Lelong,. The phylogenetically conserved molluscan chitinase-like protein 1 (Cg-Clp1), homologue of human HC-gp39, stimulates proliferation and regulates synthesis of extracellular matrix components of mammalian chondrocytes. J Biol Chem 2006;281:29583–96
59. C.G.Lee, D.Hartl, G.R.Lee,. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009;206:1149–66
60. J.S.Johansen, H.S.Jensen, P.A.Price A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993;32:949–55
61. A.D.Kjaergaard, S.E.Bojesen, J.S.Johansen, B.G.Nordestgaard Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol 2010;68:672–80
62. A.D.Kjaergaard, J.S.Johansen, B.G.Nordestgaard, S.E.Bojesen Genetic variants in CHI3L1 influencing YKL-40 levels:resequencing 900 individuals and genotyping 9000 individuals from the general population. J Med Genet 2013;50:831–7
63. J.S.Johansen, T.Lottenburger, H.J.Nielsen,. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev 2008;17:2603–8
64. K.Vuolteenaho, T.Leppänen, R.Kekkonen,. Running a marathon induces changes in adipokine levels and in markers of cartilage degradation-novel role for resistin. PLoS One 2014;9:e110481
65. J.S.Johansen, S.E.Bojesen, A.Tybjaerg-Hansen,. Plasma YKL-40 and total and disease-specific mortality in the general population. Clin Chem 2010;56:1580–91
66. S.E.Bojesen, J.S.Johansen, B.G.Nordestgaard Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta 2011;412:709–12
67. J.Kastrup, J.S.Johansen, P.Winkel,. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 2009;30:1066–72
68. C.N.Rathcke, S.B.Thomsen, A.Linneberg, H.Vestergaard Variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and prediction of fatal and non-fatal ischemic stroke. PLoS One 2012;7:e43498
69. P.M.Ridker, D.I.Chasman, L.Rose,. Plasma levels of the proinflammatory chitin-binding glycoprotein YKL-40, variation in the chitinase 3-like 1 gene (CHI3L1), and incident cardiovascular events. J Am Heart Assoc 2014;3:e000897
70. D.Bonneh-Barkay, G.Wang, A.Starkey,. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 2010;7:34
71. W.Longstreth, Jr. Brain vascular disease overt and covert. Stroke 2005;36:2062–3
72. M.Kucur, F.K.Isman, B.Karadag,. Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 2007;18:391–6
73. S.B.Thomsen, C.N.Rathcke, B.Zerahn, H.Vestergaard Increased levels of the calcification marker matrix Gla Protein and the inflammatory markers YKL-40 and CRP in patients with type 2 diabetes and ischemic heart disease. Cardiovasc Diabetol 2010;9:86
74. A.B.Mathiasen, M.J.Harutyunyan, E.Jørgensen,. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. Scand J Clin Lab Invest 2011;71:439–47
75. H.M.Kim, B.W.Lee, Y.M.Song,. Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2012;11:84
76. F.Xie, Q.Qian, Z.Chen,. Chitinase 3-like 1 gene-329G/A polymorphism, plasma concentration and risk of coronary heart disease in a Chinese population.l. Gene 2012;499:135–8
77. M.Rehli, H.H.Niller, C.Ammon,. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 2003;278:44058–67
78. X.Zhao, R.Tang, B.Gao,. Functional variants in the promoter region of Chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia. Am J Hum Genet 2007;80:12–8
79. S.K.Singh, R.Bhardwaj, K.M.Wilczynska,. A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40. J Biol Chem 2011;286:39893–903
80. A.Kruit, J.C.Grutters, H.J.T.Ruven,. A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker. Respir Med 2007;101:1563–71
81. C.Ober, Z.Tan, Y.Sun,. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 2008;358:1682–91
82. M.S.Yang, D.W.Morris, G.Donohoe,. Chitinase-3-like 1 (CHI3L1) gene and schizophrenia:genetic association and a potential functional mechanism. Biol Psychiatry 2008;64:98–103
83. M.L.Berres, S.Papen, K.Pauels,. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol 2009;50:370–6
84. M.H.Sohn, J.H.Lee, K.W.Kim,. Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy. Am J Respir Crit Care Med 2009;179:449–56
85. K.R.Nielsen, R.Steffensen, M.Boegsted,. Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. Arthritis Res Ther 2011;13:R109
86. J.L.Zheng, L.Lu, J.Hu,. Genetic polymorphisms in chitinase 3-like 1 (CHI3L1) are associated with circulating YKL-40 levels, but not with angiographic coronary artery disease in a Chinese population. Cytokine 2011;54:51–5
87. R.J.Fontana, H.J.Litman, J.L.Dienstag,. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int 2012;32:665–74
88. H.Yamamori, R.Hashimoto, K.Ohi,. A promoter variant in the chitinase 3-like 1 gene is associated with serum YKL-40 level and personality trait. Neurosci Lett 2012;513:204–8
89. D.A.Lawlor, R.M.Harbord, J.A.C.Sterne,. Mendelian randomization:using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27:1133–63
90. D.Eurich, U.P.Neumann, S.Boas-Knoop,. YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease. J Gastroenterol Hepatol 2013;28:153–60
91. B.D.W.Group Biomarkers and surrogate endpoints:preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89–95
92. R.S.Vasan Biomarkers of cardiovascular disease:molecular basis and practical considerations. Circulation 2006;113:2335–62
93. D.A.Morrow, J.A.de Lemos Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007;115:949–52
94. Y.Saitou, K.Shiraki, Y.Yamanaka,. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005;11:476–81
95. G.Esmat, M.Metwally, K.R.Zalata,. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol 2007;46:620–7
96. R.J.Fontana, Z.D.Goodman, J.L.Dienstag,. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008;47:789–98
97. P.Mehta, R.Ploutz-Snyder, J.Nandi,. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2008;103:928–36
98. S.Pungpapong, D.P.Nunes, M.Krishna,. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transpl 2008;14:1294–302
99. R.J.Fontana, H.L.Bonkovsky, D.Naishadham,. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol 2009;7:219–26
100. R.J.Fontana, J.L.Dienstag, H.L.Bonkovsky,. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010;59:1401–9
101. T.Rath, M.Roderfeld, C.Güler,. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scand J Gastroenterol 2011;46:1369–80
102. N.D.Mygind, M.J.Harutyunyan, A.B.Mathiasen,. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflamm Res 2011;60:281–7
103. P.Bedossa, D.Dargère, V.Paradis Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449–57
104. D.C.Rockey, S.H.Caldwell, Z.D.Goodman,. Liver biopsy. Hepatology 2009;49:1017–44
105. N.Junker, J.S.Johansen, L.T.Hansen,. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 2005;96:183–90